ReleaseWire

The world leader in optimized microplate solutions, Seahorse Microplates, will be exhibiting at the 5th Annual International Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS2016), in booth # 422, from January 25 to January 27, 2016 in San Diego, CA. This flagship event brings together life science research and development professionals from across the globe to chart the future of laboratory automated technologies and processes. A division of Seahorse Bioscience (a part of Agilent Technologies), Seahorse Microplates has been setting the industry standards for designing and manufacturing labware products and solutions that meet the stringent needs of the life science community, which ultimately accelerate research efforts, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.Whether it is filter plates, assay/storage plates, or reagent reservoirs, Seahorse Microplates offers an unmatched combination of experience, innovative technology, purchasing convenience, and comprehensive support to rapidly deliver products to exact specifications.

Drugs are a part of our everyday lives, helping us eat, breathe, and live easier in a myriad of ways. Prescription medication helps us cope, helps us heal, and allows us to live productive lives. The right drug can make all the difference in the world, alleviating pain and giving us the strength to manage our busy lives. Unfortunately prescriptive medication can cause financial woes too – whether you have a great insurance plan or an average one. Simply put, medication carries a heft financial burden over time, and consumers are left choosing between their pills or their prosperity. Fortunately one company has been hard at work helping medication-dependent Americans make ends meet. Discount My Prescription has made it their goal to help consumers across the country, which they accomplish by providing discount cards for prescription drugs that boast 24-94% savings for FDA-approved prescription medications. Most recently the company hit a major milestone, reaching 50,000 total downloads.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions refractory and relapsed Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). The Company has recently submitted an Investigational New Drug (IND) application for Iomab-B with the FDA and is preparing for a pivotal, Phase 3 trial.

PT-141 is considered as the ever first in the novel class of therapies (also known as melanocortin agonists) which also work via a system of action involving the central nervous system and not directly on the vascular system. What is notable about the use of PT-141 is that it offers an extensively safety and effective benefits over the readily available products like Viagra, Cialis,and Levitra.

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Pending the FDA's acceptance of the IND filing, Actinium will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55.

CEL-SCI Corporation announces that it has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy. The patent, number EP 1 753 452 B, is entitled: A METHOD FOR ALTERING THE CD4/CD8 RATIO AND THE MONONUCLEAR CELLULAR INFILTRATE INTO A TUMOR.

Tim joins Ignite Data after a varied and successful executive career, most recently as CEO of King's College Hospital NHS Foundation Trust. Prior to joining the NHS Tim worked first for Shell, then in a series of increasingly complex roles in BT, culminating in him being responsible for all BT's big contracts in the UK, including those with the NHS and with UK based pharmaceuticals.

An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries. The recently launched Phos-Cat4 has been specially designed to be just as effective as the rest of the PhosphonicS acid catalyst range but offer even more stability.

Q BioMed Inc., a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Dr. Xin Du, Ph.D., to the position of Executive Director, Regulatory Affairs and Dr. Sri Srivastava, Ph.D., PMP, to the position of Associate Director of Project Management. Dr. Srivastava will have operational responsibilities for Actinium's Actimab-A program including the planned Phase 2 trial, planning and process optimization, management of external vendors and the coordination of all clinical trial related matters. Dr. Du will be responsible for managing Actinium's regulatory submissions, CMC efforts, interacting with regulatory agencies and developing the Company's regulatory strategy as pertains to both Iomab-B, Actimab-A and all future programs. Both hires are especially timely given the planned transformation of Actinium into a later stage product development company in 2016.

GlobalData's clinical trial report, "Renal Stones/Calculi Global Clinical Trials Review, H2, 2015" provides an overview of Renal Stones/Calculi clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Stones/Calculi. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that subsequent to its pre-IND (Investigative New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its Iomab-B drug candidate, the Company is finalizing the IND filing for submission to the FDA to support the start of the Phase 3 clinical study.

REALTECH Inc. launched their newly designed website at www.realtech.us on October 1st. Introducing REALTECH as a new breed of technology transformation provider, the new website and brand refresh are more closely aligned with the company's strategic vision for growth and expansion over the next three years and beyond.

Today WENO Exchange LLC and NewCorp Inc. announced the launch of the new drug price transparency program, called BSURE, across the NewCrop eRx Network. BSURE will give 20,000 e-Prescribers early access to drug prices at the point of care — before they decide & send the prescription to the pharmacy. The BSURE plug in works independently on the physician's electronic health record (EHR) and delivers the drug price by super coordinating all of a patient's known drug benefits such as those from a health plan, a pharmaceutical coupon, and WENO's BSURE cash discount card.

Creative Biolabs is glad to announce a new series of stable cell lines services.

REALTECH Inc., is proud to announce its new proprietary business case validation calculator to measure business value towards the implementation and migration of SAP HANA. This patent-pending Business Case Validation Tool leverages customer's real data to better define what type of HANA implementation is required, level of effort, resources needed and implementation timeline. The tool is a result of over 20 years of experience in defining high value solutions from over 1,100 client engagements and provides:

The ABC Compounding Pharmacy in Los Angeles offers the unique services of specifically designing and creating customized medications for patients in the Encino and surrounding areas. This highly regarded team of board certified professional pharmacists are legally licensed in the state of California to combine precisely formulated medications at very specific amounts based on the individual and unique needs of each patient. Compounded medications can speed the recovery process while reducing the risks of potentially harmful side effects, including addiction, over medication, and allergic reactions. They can also take the form of oral, inhalant, or interveinal medications.

Nowadays, an increasing number of people who are suffering from medical conditions, such as gallbladder problems, are resorting to various natural alternatives. Ailments such as gallstones can be troublesome, and this is why many sufferers use remedies that can potentially provide them with the solution they are looking for.

"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD

A wide variety of diseases are continually affecting the lives of millions of people. The good news is that many of the prevalent medical conditions nowadays are possibly preventable through practicing a healthy diet and lifestyle, or consuming some dietary supplements such as turmeric.

Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase. Therefore, statin is referred to HMG-CoA reductase inhibitors. Statin has been associated with a beneficial effect on cardiovascular morbidity and mortality. It has significant anti-inflammatory and plaque-stabilizing effects. Its other effects include decreased oxidative stress and vascular inflammation with increased atherosclerotic lesions. Some of the currently available statins are atorvastatin, lovastatin, rosuvastatin, and simvastatin.

Strokes take place when there is a restriction in the blood flow of the brain, and the brain tissue is deprived of nutrients and oxygen for a few seconds. There are two types of stroke, and one is Ischemic stroke.

REALTECH Inc. announces its new business value driven BW to SAP HANA Implementation Solution. The unique end to end solution, utilizes business process benchmarks and business metrics to create improved business responsiveness and situational awareness that results in the optimization of revenue and reduction of operational costs. Traditionally, most organizations assess HANA based on the technical qualifications, however, the true power of HANA lies in determining how an organization can apply this to real business measures and dollars. REALTECH's point of view is that business drives technology and the REALTECH BW to SAP HANA Implementation Solution ensures organizations will effectively leverage HANA to expand its capability to handle more data and generate more insight, thus improving competitive advantage and enterprise performance.

Creative Bioarray is a well-recognized service provider which supplies comprehensive both human and animal tissue products, including Tissue Bank, Blood Sample, RNA sample, DNA sample and Body fluid, etc. Over the years, Creative Bioarray insists on providing high quality human tissue specimens, as well as animal tissue samples for its customers, making itself enjoy a great reputation among research community.

Medicortex Finland Oy has established a new diagnostic division/arm to its core business with the goal of developing a biomarker diagnostic test that would reliably establish the severity and extent of brain injuries. The companion diagnostic will be coupled with Medicortex's signature pharmaceutical therapy that will limit the long-term effects of brain injuries, including the types of severe brain trauma that leads to strokes in patients.